Are you “Team Stocks” when considering investing? Or are you “Team Real Estate”? A little bit of both? Despite stocks and real estate being the two pillars for investing, the nuances of each can be daunting. When considering what makes the most sense for your financial goals, here are some factors that could have implications regarding whether the risk is worth the reward.

Despite the COVID-19 pandemic seemingly putting a hold on everything, approvals of new drugs have not waned. In fact, despite their high price tags – median prices ranged from $766 million to $2.8 billion – new drugs continue to roll out in 2021. Here are five new drugs approved this year that you may find useful in your clinical practice of medicine.

According to research, there are numerous lesser-known supplements made from naturally occurring ingredients that boast health benefits. With only 10% of the plants from the total of natural resources for medicine investigated for therapeutic potential, many are not aware that these natural products offer potential health benefits. Here are five worth considering for their evidence-based advantages.

This article presents a review and commentary of selected presentations from the all-virtual 62nd American Society of Hematology (ASH) Meeting and Exposition, which took place in December 2020. Coverage includes safety and efficacy results from various trials and studies, including MEDALIST, DACOTA, P-2001, M15-531, ACE-536-MF-001, Sintra-REV, and COMMANDS.

These evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in their decisions about the prevention and treatment of venous thromboembolism (VTE)  – a common complication among patients with cancer who are at a markedly increased risk for morbidity and mortality.

This article presents a review and commentary of selected presentations from the all-virtual 62nd American Society of Hematology (ASH) Meeting and Exposition, which took place in December 2020. Coverage includes safety and efficacy results in trials of acalabrutinib, venetoclax, obinutuzumab, rituximab, LOXO-305, idelalisib, bendamustine, umbralisib, ublituximab, chlorambucil, lisocabtagene maraleucel, and others.